Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages

Journal of Hepatology

Volumn 66, Issue 1, 2017, Pages 102-115

  Raggi, Chiara ^a   Correnti, Margherita ^a   Sica, Antonio ^a,c   Andersen, Jesper B ^d   Cardinale, Vincenzo ^e   Alvaro, Domenico ^e   Chiorino, Giovanna ^f   Forti, Elisa ^a   Glaser, Shannon ^g   Alpini, Gianfranco ^g   Destro, Annarita ^a   Sozio, Francesca ^a,h   Di Tommaso, Luca ^a,i   Roncalli, Massimo ^a,i   Banales, Jesus M ^j   Coulouarn, Cédric ^k   Bujanda, Luis ^j   Torzilli, Guido ^a   Invernizzi, Pietro ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Laboratory of Cancer Genomics   (Italy)

^g TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j HOSPITAL DONOSTIA   (Spain)

^k PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Cancer stem cells; Cholangiocarcinoma; Tumor associated macrophages

Indexed keywords

BMI1 PROTEIN; CA 19-9 ANTIGEN; CD115 ANTIGEN; CD206 ANTIGEN; CD68 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 34; KRUPPEL LIKE FACTOR 4; LYMPHOCYTE ANTIGEN; LYMPHOID ENHANCER FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOACTIVIN; PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; CARCINOGEN; GPNMB PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENICITY; CELL ISOLATION; CONDITIONED MEDIUM; CONTROLLED STUDY; CTNNB1 GENE; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KITLG GENE; LIN28A GENE; MACROPHAGE ACTIVATION; MAML1 GENE; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL NICHE; THY1 GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; ANIMAL; BILE DUCT TUMOR; CARCINOGENESIS; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; BILE DUCT NEOPLASMS; CARCINOGENESIS; CARCINOGENS; CHOLANGIOCARCINOMA; HUMANS; INTERLEUKINS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASTIC STEM CELLS;

EID: 85000982014     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.012     Document Type: Article

References (48)

1. [1] Andersen, J.B., Spee, B., Blechacz, B.R., Avital, I., Komuta, M., Barbour, A., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142 (2012), 1021–1031, e1015.
2. [2] Blechacz, B., Gores, G.J., Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48 (2008), 308–321.
3. [3] Raggi, C., Invernizzi, P., Andersen, J.B., Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J Hepatol 62 (2015), 198–207.
4. [4] Banales, J.M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J.B., Invernizzi, P., et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13 (2016), 261–280.
5. [5] Lin, G., Liu, Y., Li, S., Mao, Y., Wang, J., Shuang, Z., et al. Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma. Oncotarget 7 (2016), 50963–50971.
6. [6] Sabbatino, F., Villani, V., Yearley, J.H., Deshpande, V., Cai, L., Konstantinidis, I.T., et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res 22 (2016), 470–478.
7. [7] Mao, Z.Y., Zhu, G.Q., Xiong, M., Ren, L., Bai, L., Prognostic value of neutrophil distribution in cholangiocarcinoma. World J Gastroenterol 21 (2015), 4961–4968.
8. [8] Sasaki, M., Tsuneyama, K., Ishikawa, A., Nakanuma, Y., Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. Hum Pathol 34 (2003), 1337–1344.
9. [9] Fan, B., Malato, Y., Calvisi, D.F., Naqvi, S., Razumilava, N., Ribback, S., et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 122 (2012), 2911–2915.
10. [10] Marquardt, J.U., Raggi, C., Andersen, J.B., Seo, D., Avital, I., Geller, D., et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 54 (2011), 1031–1042.
11. [11] Raggi, C., Factor, V.M., Seo, D., Holczbauer, A., Gillen, M.C., Marquardt, J.U., et al. Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology 59 (2014), 2251–2262.
12. [12] Kreso, A., Dick, J.E., Evolution of the cancer stem cell model. Cell Stem Cell 14 (2014), 275–291.
13. [13] Hanahan, D., Coussens, L.M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21 (2012), 309–322.
14. [14] Plaks, V., Kong, N., Werb, Z., The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell Stem Cell 16 (2015), 225–238.
15. [15] Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A 108 (2011), 12425–12430.
16. [16] Su, S., Liu, Q., Chen, J., Chen, F., He, C., Huang, D., et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25 (2014), 605–620.
17. [17] Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147 (2014), 1393–1404.
18. [18] Lu, H., Clauser, K.R., Tam, W.L., Frose, J., Ye, X., Eaton, E.N., et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 16 (2014), 1105–1117.
19. [19] Zhou, W., Ke, S.Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 17 (2015), 170–182.
20. [20] Biswas, S.K., Sica, A., Lewis, C.E., Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180 (2008), 2011–2017.
21. [21] Roberts, P.E., Isolation and establishment of human tumor stem cells. Methods Cell Biol 86 (2008), 325–342.
22. [22] Pollard, S.M., Yoshikawa, K., Clarke, I.D., Danovi, D., Stricker, S., Russell, R., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4 (2009), 568–580.
23. [23] Miyagiwa, M., Ichida, T., Tokiwa, T., Sato, J., Sasaki, H., A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 25 (1989), 503–510.
24. [24] Han, C., Wu, T., Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280 (2005), 24053–24063.
25. [25] Shimizu, Y., Demetris, A.J., Gollin, S.M., Storto, P.D., Bedford, H.M., Altarac, S., et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 52 (1992), 252–260.
26. [26] Cardinale, V., Renzi, A., Carpino, G., Torrice, A., Bragazzi, M.C., Giuliante, F., et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am J Pathol 185 (2015), 1724–1739.
27. [27] Sirica, A.E., Zhang, Z., Lai, G.H., Asano, T., Shen, X.N., Ward, D.J., et al. A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47 (2008), 1178–1190.
28. [28] Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34 (2003), 374–378.
29. [29] Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., Morrison, S.J., Efficient tumour formation by single human melanoma cells. Nature 456 (2008), 593–598.
30. [30] Raggi, C., Mousa, H.S., Correnti, M., Sica, A., Invernizzi, P., Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene 35 (2015), 671–682.
31. [31] Sica, A., Schioppa, T., Mantovani, A., Allavena, P., Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42 (2006), 717–727.
32. [32] Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362 (2010), 875–885.
33. [33] Bingle, L., Brown, N.J., Lewis, C.E., The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196 (2002), 254–265.
34. [34] Schmidt, T., Brodesser, A., Schnitzler, N., Gruger, T., Brandenburg, K., Zinserling, J., et al. CD66b overexpression and loss of C5a receptors as surface markers for staphylococcus aureus-induced neutrophil dysfunction. PLoS One, 10, 2015, e0132703.
35. [35] Solinas, G., Schiarea, S., Liguori, M., Fabbri, M., Pesce, S., Zammataro, L., et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 185 (2010), 642–652.
36. [36] Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Liu, B., et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19 (2011), 541–555.
37. [37] Pollard, J.W., Trophic macrophages in development and disease. Nat Rev Immunol 9 (2009), 259–270.
38. [38] Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11 (2010), 889–896.
39. [39] Sica, A., Mantovani, A., Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122 (2012), 787–795.
40. [40] Dang, W., Qin, Z., Fan, S., Wen, Q., Lu, Y., Wang, J., et al. MiR-1207-5p suppresses lung cancer growth and metastasis by targeting CSF1. Oncotarget 7 (2016), 32421–32432.
41. [41] Mantovani, A., Allavena, P., The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 212 (2015), 435–445.
42. [42] Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925.
43. [43] Van Overmeire, E., Laoui, D., Keirsse, J., Van Ginderachter, J.A., Sarukhan, A., Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol, 5, 2014, 127.
44. [44] Locatelli, L., Cadamuro, M., Spirli, C., Fiorotto, R., Lecchi, S., Morell, C.M., et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 63 (2016), 965–982.
45. [45] Felix, J., Elegheert, J., Gutsche, I., Shkumatov, A.V., Wen, Y., Bracke, N., et al. Human IL-34 and CSF-1 establish structurally similar extracellular assemblies with their common hematopoietic receptor. Structure 21 (2013), 528–539.
46. [46] Kuan, C.T., Wakiya, K., Dowell, J.M., Herndon, J.E. 2nd, Reardon, D.A., Graner, M.W., et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12 (2006), 1970–1982.
47. [47] Rose, A.A., Pepin, F., Russo, C., Abou Khalil, J.E., Hallett, M., Siegel, P.M., Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5 (2007), 1001–1014.
48. [48] De Minicis, S., Kisseleva, T., Francis, H., Baroni, G.S., Benedetti, A., Brenner, D., et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis 45 (2013), 450–459.